SLC5A2 and type 2 diabetes mellitus: Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral anti-hyperglycemic medications that are approved and indicated for T2D and have shown promising renoprotective effects independent of their glucose-lowering action (50).